http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 06 May 2025 12:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html <p align="center"><em>Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry</em></p> <p align="center"><em>Laru-zova was generally well-tolerated by DAWN participants at 6 months</em></p> <p align="justify">LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis http://www.streetinsider.com/Globe+Newswire/Beacon+Therapeutics+Announces+Positive+Phase+2+Interim+6-Month+Data+from+DAWN+Trial+of+Laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2025/24748397.html Tue, 06 May 2025 12:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50201098 A.60012014 AGTC O.02147044 O.18709770 O.20026344 O.20032830 http://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++APPLIED+GENETIC+TECHNOLO+++++++++++++++Filed+by%3A+Beryl+Capital+Management+LLC/21220249.html si-local-file:///var/storage/secattach/20230214/21220249.html http://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++APPLIED+GENETIC+TECHNOLO+++++++++++++++Filed+by%3A+Beryl+Capital+Management+LLC/21220249.html Tue, 14 Feb 2023 13:22:00 -0400 AGTC http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++APPLIED+GENETIC+TECHNOLO+++++++++++++/20956828.html si-local-file:///var/storage/secattach/20221212/20956828.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++APPLIED+GENETIC+TECHNOLO+++++++++++++/20956828.html Mon, 12 Dec 2022 08:34:00 -0400 AGTC http://www.streetinsider.com/SEC+Filings/Form++SC+13D+++++APPLIED+GENETIC+TECHNOLO+++++++++++++++Filed+by%3A+Tetragon+Financial+Management+LP/20948682.html si-local-file:///var/storage/secattach/20221208/20948682.html http://www.streetinsider.com/SEC+Filings/Form++SC+13D+++++APPLIED+GENETIC+TECHNOLO+++++++++++++++Filed+by%3A+Tetragon+Financial+Management+LP/20948682.html Thu, 08 Dec 2022 12:42:00 -0400 AGTC http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++APPLIED+GENETIC+TECHNOLO+++++++++++++/20940779.html si-local-file:///var/storage/secattach/20221207/20940779.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++APPLIED+GENETIC+TECHNOLO+++++++++++++/20940779.html Wed, 07 Dec 2022 06:04:00 -0400 AGTC http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++APPLIED+GENETIC+TECHNOLO+++++++++++++/20940786.html si-local-file:///var/storage/secattach/20221207/20940786.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++APPLIED+GENETIC+TECHNOLO+++++++++++++/20940786.html Wed, 07 Dec 2022 06:04:00 -0400 AGTC